Analysts Set Bruker Corporation (BRKR) Target Price at $26.70

Shares of Bruker Corporation (NASDAQ:BRKR) have been assigned a consensus recommendation of “Hold” from the fifteen analysts that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $26.70.

A number of equities analysts have recently weighed in on the stock. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and set a $24.00 price target on shares of Bruker Corporation in a research note on Tuesday, September 26th. Zacks Investment Research raised shares of Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research note on Thursday, July 6th. Barclays PLC reaffirmed an “equal weight” rating and set a $30.00 price target (up from $26.00) on shares of Bruker Corporation in a research note on Monday, July 17th. Wells Fargo & Company lowered shares of Bruker Corporation from a “market perform” rating to an “underperform” rating in a research report on Wednesday, July 12th. Finally, Cowen and Company reiterated a “hold” rating and issued a $29.00 price objective on shares of Bruker Corporation in a research report on Friday, July 14th.

ILLEGAL ACTIVITY WARNING: This news story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2017/10/16/analysts-set-bruker-corporation-brkr-target-price-at-26-70.html.

Shares of Bruker Corporation (NASDAQ BRKR) opened at 30.89 on Wednesday. Bruker Corporation has a one year low of $19.59 and a one year high of $30.97. The company’s 50-day moving average is $29.71 and its 200-day moving average is $27.44. The stock has a market capitalization of $4.90 billion, a P/E ratio of 30.80 and a beta of 1.09.

Bruker Corporation (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.03. The company had revenue of $414.90 million for the quarter, compared to analysts’ expectations of $384.75 million. Bruker Corporation had a net margin of 9.65% and a return on equity of 26.66%. Bruker Corporation’s revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.20 EPS. On average, equities research analysts anticipate that Bruker Corporation will post $1.12 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 22nd. Investors of record on Tuesday, September 5th were paid a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend was Thursday, August 31st. Bruker Corporation’s dividend payout ratio (DPR) is presently 16.00%.

In other news, VP Mark Munch sold 21,061 shares of the firm’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total transaction of $631,198.17. Following the transaction, the vice president now directly owns 60,524 shares of the company’s stock, valued at $1,813,904.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Frank H. Laukien purchased 2,335 shares of the stock in a transaction dated Thursday, August 10th. The shares were acquired at an average cost of $27.39 per share, for a total transaction of $63,955.65. Following the completion of the acquisition, the chief executive officer now directly owns 37,791,386 shares of the company’s stock, valued at approximately $1,035,106,062.54. The disclosure for this purchase can be found here. Company insiders own 35.20% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Acrospire Investment Management LLC increased its holdings in shares of Bruker Corporation by 496.1% during the second quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 3,185 shares during the period. SG Americas Securities LLC acquired a new position in Bruker Corporation during the second quarter worth about $111,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Bruker Corporation by 11.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock worth $133,000 after acquiring an additional 467 shares during the period. Smithfield Trust Co. acquired a new position in Bruker Corporation during the second quarter worth about $138,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Bruker Corporation by 7.1% during the second quarter. The Manufacturers Life Insurance Compa

A number of equities analysts have recently weighed in on the stock. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and set a $24.00 price target on shares of Bruker Corporation in a research note on Tuesday, September 26th. Zacks Investment Research raised shares of Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research note on Thursday, July 6th. Barclays PLC reaffirmed an “equal weight” rating and set a $30.00 price target (up from $26.00) on shares of Bruker Corporation in a research note on Monday, July 17th. Wells Fargo & Company lowered shares of Bruker Corporation from a “market perform” rating to an “underperform” rating in a research report on Wednesday, July 12th. Finally, Cowen and Company reiterated a “hold” rating and issued a $29.00 price objective on shares of Bruker Corporation in a research report on Friday, July 14th.

ILLEGAL ACTIVITY WARNING: This news story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2017/10/16/analysts-set-bruker-corporation-brkr-target-price-at-26-70.html.

Shares of Bruker Corporation (NASDAQ BRKR) opened at 30.89 on Wednesday. Bruker Corporation has a one year low of $19.59 and a one year high of $30.97. The company’s 50-day moving average is $29.71 and its 200-day moving average is $27.44. The stock has a market capitalization of $4.90 billion, a P/E ratio of 30.80 and a beta of 1.09.

Bruker Corporation (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.03. The company had revenue of $414.90 million for the quarter, compared to analysts’ expectations of $384.75 million. Bruker Corporation had a net margin of 9.65% and a return on equity of 26.66%. Bruker Corporation’s revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.20 EPS. On average, equities research analysts anticipate that Bruker Corporation will post $1.12 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 22nd. Investors of record on Tuesday, September 5th were paid a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend was Thursday, August 31st. Bruker Corporation’s dividend payout ratio (DPR) is presently 16.00%.

In other news, VP Mark Munch sold 21,061 shares of the firm’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total transaction of $631,198.17. Following the transaction, the vice president now directly owns 60,524 shares of the company’s stock, valued at $1,813,904.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Frank H. Laukien purchased 2,335 shares of the stock in a transaction dated Thursday, August 10th. The shares were acquired at an average cost of $27.39 per share, for a total transaction of $63,955.65. Following the completion of the acquisition, the chief executive officer now directly owns 37,791,386 shares of the company’s stock, valued at approximately $1,035,106,062.54. The disclosure for this purchase can be found here. Company insiders own 35.20% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Acrospire Investment Management LLC increased its holdings in shares of Bruker Corporation by 496.1% during the second quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 3,185 shares during the period. SG Americas Securities LLC acquired a new position in Bruker Corporation during the second quarter worth about $111,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Bruker Corporation by 11.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock worth $133,000 after acquiring an additional 467 shares during the period. Smithfield Trust Co. acquired a new position in Bruker Corporation during the second quarter worth about $138,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Bruker Corporation by 7.1% during the second quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after acquiring an additional 331 shares during the period. 65.42% of the stock is currently owned by institutional investors.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply